Chemistry: molecular biology and microbiology – Vector – per se
Patent
1995-02-15
1998-10-06
Ketter, James
Chemistry: molecular biology and microbiology
Vector, per se
435 93, 4351723, 4241991, 4242171, C12N 1543, C12P 2102, A61K 3913
Patent
active
058175121
ABSTRACT:
The present invention pertains to a method of encapsidating a recombinant poliovirus nucleic acid to obtain a yield of encapsidated viruses which substantially comprises encapsidated recombinant poliovirus nucleic acid. The method of encapsidating a recombinant poliovirus nucleic acid includes contacting a host cell with a recombinant poliovirus nucleic acid which lacks the nucleotide sequence encoding at least a portion of a protein necessary for encapsidation and an expression vector comprising a nucleic acid which encodes at least a portion of one protein necessary for encapsidation under conditions appropriate for introduction of the recombinant poliovirus nucleic acid and the expression vector into the host cell and obtaining a yield of encapsidated viruses which substantially comprises an encapsidated recombinant poliovirus nucleic acid. A foreign nucleotide sequence is generally substituted for the nucleotide sequence of the poliovirus nucleic acid encoding at least a portion of a protein necessary for encapsidation. The invention further pertains to encapsidated recombinant poliovirus nucleic acids produced by the method of this invention and compositions containing the encapsidated or nonencapsidated recombinant poliovirus nucleic acid containing a foreign nucleotide sequence for use in a method of stimulating an immune response in a subject to the protein encoded by the foreign nucleotide sequence.
REFERENCES:
Kantor et al. Antitumor activity and immune responses inducted by a recombinant carcinoembryonic antigen-vaccinia virus vaccine J. Natl. Cancer Institute vol. 84 1084-1091, 1992.
Knuth et al. Cellular and humoral immune responses against cancer: implications for cancer vaccines Current Opinion in Immunol. vol. 3 659-664 1991.
Fox No winners against AIDS Biotechnology vol. 12 128, 1994.
Choi et al. Expression of human immunodeficiency virus type 1 (HIV-1) gag, pol, and env proteins from chimeric HIV-1-poliovirus minireplicons J. Virol. vol. 65 2875-2883, 1991.
Ansardi, D.C. et al. (1994) "Characterization Poliovirus Repilicons Encoding Carcinoembryonic Antigen" Cancer Research 54:6359-6364.
Ansardi, D.C. et al. (1991) "Coinfection with Recombinant Vaccinia Viruses Expressing Poliovirus P1 and P3 Proteins Results in Polyprotein Processing and Formation of Empty Capsid Structures" J. Virol. 65(4):2088-2092.
Ansardi, D.C. et al. (1993) "Complementation of a Poliovirus Defective Genome by a Recombinant Vaccinia Virus Which Provides Poliovirus P1 Capsid Precursor in trans" J. Virol. 67(6):3684-3690.
Ansardi, D.C. et al. (1992) "Myristylation of Polivirus Capsid Precursor P1 Is Required for Assembly of Subviral Particles" J. Virol. 66(7):4556-4563;.
Choi, W.S. et al. (1991) "Expression of Human Immunodeficieny Virus Type 1 (HIV-1) gag, pol, and env Proteins from Chimeric HIV-1-Poliovirus Minireplicons"J. Virol 65(6):2875-2883.
Evans, D.J. et al. (1989) "An Engineered Poliovirus Chimaera Elicits Boradly Reactive HIV-1 Neutralizing Antibodies" Nature 339:385-388;.
Haynes, B.F. (1993) "Scientific and Social Issues of Human Immunodeficiency Virus Vaccine Development" Science 260: 1279-1286.
Jenkins, O. et al. (1990) "An Anitgen Chimera of Polivirus Induces Antibodies against Human Papillomavirus Type 16" J. Virol. 64(3):1201-1206.
McGhee, J.R. and Mestecky, J. (1992) "The Mucosal Immune System in HIV Infection and Prospects for Mucosal Immunity to AIDS" in AIDS Research Reviews, W.C. Koff et al. (eds.), New York: Marcel Dekker, Inc., 2:Ch. 15, 289-312.
Moldoveanu, Z. et al. (1995) "Immune Response s Induced by Administration of Encapsidated Poliovirus Replicons Which Express HIV-1 gag and env Proteins" FASEB J. 9(3):A214, No. 1247.
Morrow, C.D. et al. (1994) "New Approaches for Mucosal Vaccines for AIDS: Encapisadation and Serial Passage of Poliovirus Repilicons that Express HIV-1 Proteins on Infection" AIDS Research and Human Retroviruses 10 Suppl. 1:S61-S66.
Percy, N. et al. (1992) "A Poliovirus Replicon Containing the Chloramphenicol Acetytranferase Gene Can Be Used To Study the Replicon and Encapsidation of Poliovirus RNA" J. Virol. 66(8):5040-5046.
Porter, D.C. et al. (1993) "Encapsidation of Genetically Engineered Poliovirus Minireplicons Which Express Human Immunodeficiency Virus Type 1 Gag and Pol Proteins upon Infection" J. Virol. 67(7):3712-3719.
Porter, D.C. et al. (1993) "Expression of Poliovirus P3 Proteins Using a Recombinant Vaccinia Virus Results in Proteolytically Active 3CD Precursor Protein Without Further Processing to 3C.sup.pro and 3D.sup.pol " Virus Research 29:241-254.
Porter, D.C. et al. (Mar. 13-18, 1993) "Encapsidation of Chimeric HIV-1-Poliovirus Minireplicons"J. Cell Biochem. Suppl. 17 (D): p. 26.
Ansardi, D.C. et al. (Mar. 13-18, 1993) "Molecular Analysis of Poliovirus Assembly Using Recombinant Vaccinia Viruses to Complement A Poliovirus Genome With A Capsid Gene Deletion" J. Cell Biochem. Suppl. 17 (D); p. 22.
Porter, D. et al., "Encapsidation of Poliovirus Replicons Encoding the Complete Human Immunodeficiency Virus Type 1 gag Gene by Using a Complementation System Which Provides the P1 Capsid Protein in trans," Journal of Virology, vol. 69, No. 3, 1548-1555 (Mar. 1995).
Ansardi David C.
Morrow Casey D.
Porter Donna C.
Brusca John S.
Ketter James
Silveri Jean M.
The UAB Research Foundation
LandOfFree
Encapsidated recombinant viral nucleic acid and methods of makin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Encapsidated recombinant viral nucleic acid and methods of makin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Encapsidated recombinant viral nucleic acid and methods of makin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-76227